Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812)-Reference-Cited by-同舟云学术

Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812)

Published:2021-05 Issue:4 Volume:12 Page:563-571
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Maggiore Ronald J.,Zahrieh David,McMurray Ryan P.,Feliciano Josephine L.,Samson Pamela,Mohindra Pranshu,Chen Hongbin,Wong Melisa L.,Lafky Jacqueline M.,Jatoi Aminah,Le-Rademacher Jennifer G.

Funder

National Cancer Institute

National Institute on Aging

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference43 articles.

1. SEER Cancer Statistics Review, 1975‐2016,2020

2. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999

3. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011

4. Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

5. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial;Socinski;Cancer.,2001

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer (LOGIK1902);Thoracic Cancer;2024-09-08

2. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China;PLOS ONE;2023-06-01

3. Population and environmental-specific considerations;Translational Radiation Oncology;2023

4. A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial;Frontiers in Oncology;2022-03-31

5. Understanding Treatment Tolerability in Older Adults With Cancer;Journal of Clinical Oncology;2021-07-01